Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial.
Assenat E, Pageaux GP, Thézenas S, Peron JM, Bécouarn Y, Seitz JF, Merle P, Blanc JF, Bouché O, Ramdani M, Poujol S, de Forges H, Ychou M, Boige V.
Assenat E, et al.
Br J Cancer. 2019 Apr;120(9):896-902. doi: 10.1038/s41416-019-0443-4. Epub 2019 Apr 4.
Br J Cancer. 2019.
PMID: 30944458
Free PMC article.
Clinical Trial.